Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. - Wikidata - wikimedia - TriplyDB

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

http://www.wikidata.org/entity/Q35551028

about

Ofatumumab SLE - Rituximab in lupus In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration A case-control study of rheumatoid arthritis identifies an associated single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-oxidase complex in autoimmunity.The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.B cell depletion in autoimmune disease.Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus.Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab Treating human autoimmune disease by depleting B cells Immunotherapy for autoimmune and inflammatory renal diseases.CD3-positive B cells: a storage-dependent phenomenon B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience Update on rituximab.Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Targeting B cells for the treatment of rheumatoid arthritis Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis.B cell signalling as therapeutic target.Cell therapy for autoimmune diseases: does it have a future?Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.New therapies for rheumatoid arthritis.B cells as a therapeutic target in autoimmune diseases.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Rituximab treatment of refractory rheumatoid arthritis.Metabolism and transport of oxazaphosphorines and the clinical implications.Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.Rituximab: applications in dermatology.Epratuzumab in the therapy of oncological and immunological diseases.Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

P2860

Q24651912-B071AAF5-70AE-4E39-B81B-E55561FD69BF Q24804739-AD726A25-A516-496D-959D-36392AE4E3AC Q28752150-4283FAD2-7A38-47FC-ADBB-5084AC6C31D8 Q31046441-B5D2EED5-F142-42F4-A9E3-B03D920ED51C Q33300467-82D08748-7023-4766-97E5-456FE2ECD21A Q33360255-EEA5575C-623C-4348-BD39-530B30D91AF7 Q33361142-EFDFA837-900D-4D96-A4FD-2EAFE0FC4D40 Q33370836-1E886950-22F7-4156-9683-A27CD5090FBF Q33371491-026BAC4D-43E2-4C73-A714-B7EB3588A4BA Q33401100-0C6E2786-4482-4F2C-926F-BF103B6BFDA3 Q33421410-EA9E1CD7-1246-4041-81B1-4E8F142E924D Q33494191-96D781DC-4847-4246-A7D7-97A161117920 Q33695997-0F9E9987-1CB3-42D1-86B8-D3BF41EE8F75 Q33741009-9DBD0CF3-51BC-4EEB-AA05-1C725200E5E7 Q34848963-95CBACD3-12B2-47D4-B2C2-5DF68B462C75 Q35144046-1B90FA87-0B8E-4CC2-863A-D2AEAFC596DD Q35346760-FAFE57E1-1B7E-44F9-BBC6-5C9366BC5739 Q35553501-6A531EB3-33BA-41D3-98BB-C0CB46A853E4 Q35579499-13C81518-500E-4BAB-9435-717AD678739E Q35760171-2B8FEF62-EDB8-44B2-AB31-BBCCCB61C3ED Q35794365-6834C48F-ADE7-48DC-AE2F-4C0C41009D67 Q35794369-190EA629-487B-4017-A98A-19FCB026466B Q35824478-1A252A2C-E5A5-4EA8-96DA-1D41773CD019 Q35911103-2C0FC627-BB9A-4913-9629-74F8CA190460 Q35915979-8B8ADEE6-F054-4869-91D9-AB3B2B63FFF2 Q35916008-E9B2EBE7-11C6-4C23-B56A-8B620BD36D65 Q36060036-525B0EC4-191A-46AB-B572-FDD4399D2DC0 Q36088058-27C2B7DA-92FE-4D1F-9EC3-BAFF76912CEC Q36088346-D8BACD20-72AB-4E28-AAF6-BB1C4B2FFBDE Q36158684-CAA95B1B-C39D-4546-89D5-12C30024C4F7 Q36171750-506988AE-29F2-47EF-ACEA-D546789A2F00 Q36297074-FF4A7E8D-A03F-4E3E-933B-FF1742B95FC6 Q36360811-325E9123-4FE0-400B-A933-9F7F80DA744A Q36525240-D1D3B7FB-F636-498F-B5DB-42183BDF4EDF Q36532571-CD7553D7-82B9-41FA-BC80-2C98480F705C Q36577391-BC365A81-1054-4C3B-907A-B4D6CBA47B0C Q36623217-E0BF34D2-EC66-422D-B428-9C557D8C404A Q36636619-25ADF67B-83FA-42B5-B9E0-017F0B486D58 Q36752014-ED1E66A4-538F-4F19-8196-FB2F8B8BFC5A Q36807999-F4090C8A-320A-4DB4-9668-3AA328826121

P2860

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

http://www.wikidata.org/entity/Q35551028

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Clinical outcome in 22 patient ...... d with B lymphocyte depletion.

@ast

Clinical outcome in 22 patient ...... d with B lymphocyte depletion.

@en

type

label

Clinical outcome in 22 patient ...... d with B lymphocyte depletion.

@ast

Clinical outcome in 22 patient ...... d with B lymphocyte depletion.

@en

prefLabel

Clinical outcome in 22 patient ...... d with B lymphocyte depletion.

@ast

Clinical outcome in 22 patient ...... d with B lymphocyte depletion.

@en

P1433

Q35551028-D66E5015-E4A9-425E-B08E-EF424BF5B3A5

P1476

Q35551028-9FF147CF-7B02-4F98-A17C-D737FC924A0E

P2093

Q35551028-46398E3A-83F1-40D6-A48B-788DC394240F

Q35551028-77953E19-F9B2-4390-B5CE-F76628B5B5AF

Q35551028-7D324317-D54B-47E1-864B-B4A2981FA2DC

P2860

Q35551028-0FF47062-5A8D-44C7-BC2C-30527600CCA0

Q35551028-11830CE6-9C3D-41D3-A087-5D41F757A34A

Q35551028-15DE4472-D50C-40DF-98BB-75AE16207C66

Q35551028-2303347C-7A45-4DC7-922E-DA6BF86CC7E6

Q35551028-2EA95DE9-9967-44E6-94B2-C5CD4847E6C9

Q35551028-31457345-0EBC-429A-B3BF-DABD829294FE

Q35551028-5EE57D52-4F04-49E6-BB42-9A9C70AD56F9

Q35551028-64427EC1-5550-4C76-BE9A-DF06101F13A1

Q35551028-70326B3F-69C2-4E2A-87C8-3DF0E76D72BC

Q35551028-851B4979-B7F0-4A23-A75D-30B5C4137054

P304

Q35551028-DDC61EF6-1898-4309-958E-3CAF3B8A0302

P31

Q35551028-94FBBC03-9489-4ADD-BFAD-DD54524A89F8

P356

Q35551028-7F26D30C-C715-49C6-B451-B26B7D307031

P407

Q35551028-E454D443-4077-47B4-AAFB-78B1B4E58E6E

P433

Q35551028-404D273F-BF71-46FA-9921-9FB8DC048D80

P478

Q35551028-9423221D-46CE-41B9-B3A5-9757329225FC

P577

Q35551028-B23CD74E-8768-4A60-AEF3-AE5C89C49E0D

P5875

Q35551028-C9396BEE-72DD-4F2A-B06E-53CF148E05D1

P698

Q35551028-B254C757-AE66-4432-AFBA-AED0A40AD234

P932

Q35551028-8A8A5818-30DA-4A2B-ACAE-991CD8A2BBD0

P356

P1433

Annals of the Rheumatic Diseases

P1476

Clinical outcome in 22 patient ...... d with B lymphocyte depletion.

@en

P2093

Cambridge G

http://www.w3.org/2001/XMLSchema#string

Edwards JC

http://www.w3.org/2001/XMLSchema#string

Leandro MJ

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Clinical applications of anti-CD20 antibodies.

Divergent T-cell cytokine patterns in inflammatory arthritis

IgG rheumatoid factors and self-association of these antibodies.

Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.

The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.

P304

883-888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.61.10.883

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11161903

http://www.w3.org/2001/XMLSchema#string

P698

12228157

http://www.w3.org/2001/XMLSchema#string

P932

1753912

http://www.w3.org/2001/XMLSchema#string